Top

Breast Cancer Research and Treatment

Published in:

01-11-2018 | Rebuttal Letter

Re: Elevated BMI might more significantly affect the outcome negatively in luminal type breast cancer patients with brain metastases

Authors: Brittany A. Simone, Kevin Ko, Nicole L. Simone

Published in: Breast Cancer Research and Treatment | Issue 2/2018

Excerpt

Dear Editor, …

McCall NS, Simone BA, Mehta M, Zhan T, Ko K, Nowak-Choi K, Rese A, Venkataraman C, Andrews DW, Anne PR, Dicker AP, Shi W, Simone NL (2018) Onco-metabolism: defining the prognostic significance of obesity and diabetes in women with brain metastases from breast cancer. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-018-4880-1 CrossRefPubMed

Kaidar-Person O, Meattini I, Jain P, Bult P, Simone N, Kindts I, Steffens R, Weltens C, Navarria P, Belkacemi Y, Lopez-Guerra J, Livi L, Baumert BG, Vieites B, Limon D, Kurman N, Ko K, Yu JB, Chiang V, Poortmans P, Zagar T (2018) Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study. Breast Cancer Res Treat 167(2):479–483. https://doi.org/10.1007/s10549-017-4526-8 CrossRefPubMed

Kroenke CH, Chen WY, Rosner B, Holmes MD (2005) Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 23(7):1370–1378. https://doi.org/10.1200/JCO.2005.01.079 CrossRefPubMed

Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, Goodman MT, Giuliano AE, Karanja N, McAndrew P, Hudis C, Butler J, Merkel D, Kristal A, Caan B, Michaelson R, Vinciguerra V, Del Prete S, Winkler M, Hall R, Simon M, Winters BL, Elashoff RM (2006) Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst 98(24):1767–1776. https://doi.org/10.1093/jnci/djj494 CrossRefPubMed

Title: Re: Elevated BMI might more significantly affect the outcome negatively in luminal type breast cancer patients with brain metastases
Authors: Brittany A. Simone
Kevin Ko
Nicole L. Simone
Publication date: 01-11-2018
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-018-4940-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2018

Fluidic shear stress increases the anti-cancer effects of ROS-generating drugs in circulating tumor cells

Substantial evidence for the clinical significance of missense variant BRCA1 c.5309G>T p.(Gly1770Val)

Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)

Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer

Genetic polymorphisms of 3′-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy

The association between estrogen receptor alpha gene rs746432 polymorphism and the risk of breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer